Nanostructured Drug Market –Regional Insights
Based on the region, the global NanostructuredDrug Treatment Market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa. North America holds the dominantposition in the global nanostructured drug market, owing to massive funding bythe government for the nanotechnology research. For instance, According to astudy led by Lux Research with funding support from U.S. national Foundationand U.S. National Nanotechnology Coordination Office in 2013, around US$ 1.9billion was funded in 2011 and US$ 2.1 billion in 2012 for nanotechnologyresearch and development (R&D). Moreover, increasing awareness among thepopulation regarding various chronic diseases and well established healthcareinfrastructure is expected to propel the nanostructured drug market growth overthe forecast period.
Asia pacific is expected to gainsignificant market share in the nanostructured drug market, followed by Europe,owing to increasing number of population susceptible to various chronicdiseases such cancer, HIV, and tuberculosis. For instance, according to theNational Health and Family Planning Commission of the PRC report in 2015,around 533 out of 100,000 people died from chronic disease in 2012 in China,accounting for 86.6% of all deaths.
Nanotechnology is an emergingfield of science that involves atomic or molecular level manipulation ofmatter. A nanometer is equals to 1 billionth of a meter. Nanotechnology hasvarious application in different fields such as chemical sensors, batteries,food, fuel cells, solar cells, fabric, fuels, electronics, space, better airquality, cleaner water, and sporting goods. One of the key application ofnanotechnology is in medicine, nano-medicine ranges from the medicalapplication such as biological device, nanomaterial, nanoelectronic biosensors,and biological machines.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1841
Nanotechnology has presented theoption of drug delivery to specific target cells employing nanoparticles.Particles are engineered to attach to diseases cells, which allows of directtreatment of those cells. Drug delivery techniques are designed to reduce theside effects associated with the drugs along with decrease in its consumptionand treatment costs. Nanostructured drugs have various applications such as inneurology, cardiovascular/physiology, anti-inflammatory/immunology,anti-infective, and others.
Nanostructured Drug MarketDynamics
Nanostructured drugs are gainingsignificant traction in research and development due to the benefits offered bythem in terms of bioavailability, drug stability, shelf-life and dosage.Effective and safe drug delivery is a major challenge in biotechnology andpharmaceutical manufacturers. Novel techniques such as nanotechnology are beingintroduced by companies to produce innovative product, which is driving growthof the nanostructured drug market. For instance, in 2015, the Food and DrugAdministration (FDA) approved Onivyde, an irinotecan liposome injection bymerrimack pharmaceuticals, which is a prescription medicine used to treatpancreatic cancer. Onivyde is administered in combination with two other drugs,leucovorin and fluorouracil. Onivyde consists of a chemotherapy drug calledirinotecan, which interrupts cell reproduction. Irinotecan is trapped into ananostructure called liposome. Liposomes are programmed to release drug slowlywithin the interval of time.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/nanostructured-drug-market-1841
Moreover, increased funding andrevenue from nano-enabled products have propelled growth of nanostructured drugmarket. For instance, According to the National Science Foundation 2014 marketreport, the global funding for emerging nanotechnology increased by 40% to 45%for past three years. Furthermore, worldwide revenue generated by nano-enabledproducts have been increased from US$ 339 billion in 2010 to US$ 731 billion in2012, and to more than US$1 trillion in 2013.
However, high cost required forthe development of nanostructured drugs and safety risks associated withnanostructured drugs such as the duration of time nanoparticles remain in thebody, which affects cellular and tissue functions is restraining the marketgrowth.
Nanostructured Drug Market –Competitive Landscape
The key players operating in theglobal nanostructured drug market include Nanoviricides Inc., Ablynx NV, PfizerInc., Nanotherapeutics Inc., Arrowhead Research Inc., Abraxis Inc., Merck,Bio-Gate AG, and Celgene Corporation. Market players are focused on adopting ofstrategies such as increasing funding, acquisition, and collaboration tostrengthen their product portfolio and to hold dominant position in the market,For instance, in 2016, Pfizer Inc. received bankruptcy-court approval to buyall asserts of Bind Therapeutics a biotechnology company developing targetedand programmable therapeutics (nanomedicine) called ACCURINS.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1841
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
